Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

OCRX 3.78 -0.14 (-3.57%)
price chart
Ocera Therapeutics Reports Second Quarter 2015 Financial Results
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations.
Ocera Therapeutics Inc.: Ocera Therapeutics Reports Second Quarter 2015 ...  The Wall Street Transcript
Ocera Therapeutics (OCRX) Posts Quarterly Earnings Results, Misses Estimates ...  sleekmoney
Ocera (formerly Tranzyme) extends cash runway with $20M debt facility
Drug developer Ocera Therapeutics, Inc. (Nasdaq: OCRX) could borrow up to $20 million, extending the company's cash runway into at least mid-2017.
Company Shares of Ocera Therapeutics, Inc. Rally 1.03%
Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) rose by 1.03% in the past week and 7.69% for the last 4 weeks. The shares have underperformed the S&P 500 by 0.13% during the past week but Ocera Therapeutics, Inc. (NASDAQ:OCRX) has ...
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and ...
Ocera Therapeutics, Inc. OCRX, -0.26% a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it secured a $20 million debt facility from Oxford Finance LLC (Oxford) and Silicon Valley Bank ...
Ocera Therapeutics, Inc. (OCRX) Files Form 4 Insider Buying : Wendall Wierenga ...
Ocera Therapeutics, Inc. (OCRX): Wendall Wierenga , director of Ocera Therapeutics, Inc. purchased 5,000 shares on Jun 23, 2015.
Gaurav Aggarwal Paid for 7500 Shares of Ocera Therapeutics Inc (NASDAQ:OCRX)
Mr. Gaurav Aggarwal, the current Chief Business Officer at Ocera Therapeutics Inc (NASDAQ:OCRX) 3.92 +0.09 2.35% has a few days ago been connected with a stock market deal of 7,500 shares of the -listed company, valued at $3.6 per share.
Gaurav Aggarwal Acquires 7500 Shares of Ocera Therapeutics Stock (OCRX)  sleekmoney
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference
PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) Analyst Rating Update
Ocera Therapeutics Inc (NASDAQ:OCRX) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks.
Tranzyme Inc (OCRX) news: The Long-Term Risks About Ocera Therapeutics
The Long-Term Risks About Ocera Therapeutics. Introduction. Ocera Therapeutics (NASDAQ:OCRX) is a company with one main value driver, OCR002.